| 54.77 Delayed Data As of Oct 23 |  +0.35 / +0.64%Today’s Change | 42.48 Today|||52-Week Range 57.37 | +5.37% Year-to-Date |
| 3 Cancer Treatment Stocks to Buy Right Now Oct 23 / MotleyFool.com - Paid Partner Content | Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding? Oct 11 / MotleyFool.com - Paid Partner Content |
| Is Mirati Therapeutics a Good Stock to Buy Now? Oct 20 / MotleyFool.com - Paid Partner Content |
| Previous close | 54.42 |
| Today’s open | 54.41 |
| Day’s range | 53.87 - 54.82 |
| Volume | 13,165,181 |
| Average volume (3 months) | 12,131,762 |
| Market cap | $86.7B |
| Earnings growth (last year) | +393.92% |
| Earnings growth (this year) | +7.78% |
| Earnings growth (next 5 years) | +10.10% |
| Revenue growth (last year) | +8.59% |
| P/E ratio | 14.5 |
| Price/Sales | 3.77 |
| Price/Book | 6.14 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVONovo Nordisk | +0.21 | +0.39% |
| CELGCelgene | +0.29 | +0.28% |
| LLYEli Lilly and Co | -2.44 | -2.22% |
| GSKGlaxoSmithKline | +0.75 | +1.76% |
| Next reporting date | October 31, 2019 |
| EPS forecast (this quarter) | $1.07 |
| Annual revenue (last year) | $22.6B |
| Annual profit (last year) | $4.9B |
| Net profit margin | 21.81% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
